Short answer
Rezolute, Inc. (RZLT) filed its Q3 2026 10-Q quarterly report on Nov 5, 2026 for the quarter ended Sep 30, 2026.
Q3 2026 key financials · XBRL
- Net income
- −$18M
- −1.9% YoY
- EPS (diluted)
- −$0.18
- +0.0% YoY
Source: XBRL data from the Rezolute, Inc. (RZLT) Q3 2026 10-Q on SEC EDGAR. USD.
Rezolute, Inc. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $0 for Q3 2026, unchanged from $0 in Q3 2025
- Net loss $18.5M vs $18.2M YoY, no operating margin disclosed
- Tumor HI upLIFT: 7 of first 8 participants met responder criteria, all discontinued intravenous glucose
- Cash and investments $90.0M at September 30, 2026, sufficient for at least 12 months
- Operating cash outflow $18.8M vs $17.4M YoY, with $15.8M investing cash inflow
Risk Factors
- Newly added regulatory risk: FDA pre-BLA recommendation may not support ersodetug approval for congenital HI
- Clinical-development risk: FDA could require another sunRIZE-like study, delaying BLA submission and increasing costs
- Newly added trial risk: Phase 3 upLIFT topline results expected December 2026 may fail to meet endpoints for tumor HI approval
- Carried-forward risks: 2026 Form 10-K risk factors otherwise unchanged materially
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Rezolute, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.